Alaunos Therapeutics (TCRT) Registration Filing summary

Company overview and business model

• Focused on developing a preclinical small molecule oral obesity program with a differentiated, non-hormonal mechanism of action, aiming to address limitations of current obesity therapies.

• Previously operated as a clinical-stage oncology cell therapy company but reprioritized in August 2023, winding down TCR-T programs due to high costs and challenging financing.

• Exploring strategic alternatives including acquisitions, mergers, asset sales, partnerships, or capital raises.

Financial performance and metrics

• No product revenue generated to date; significant net losses incurred each year since inception.

• Net loss of $2.1 million for the six months ended June 30, 2025; accumulated deficit of $922.6 million since 2003.

• Research and development expenses for cancer programs declined from $11.7 million (six months ended June 30, 2023) to $0.3 million (same period in 2025) due to strategic reprioritization.

• Stockholders' equity was $3.66 million as of June 30, 2025, after previously falling below Nasdaq's $2.5 million minimum.

Use of proceeds and capital allocation

• Net proceeds from the Mast Hill equity line and other offerings will be used for working capital, general corporate purposes, sales and marketing, product development, and potential acquisitions or investments.

• Management retains broad discretion over allocation of proceeds; amounts and timing not specifically determined.

• No proceeds will be received from the resale of shares by selling stockholders.